Biotechnology

Clinical evidence, research, and medical intelligence in Biotechnology.

Microbial diterpene biosynthesis reaches commercial-scale titers

A review details engineered microbes producing high-value diterpenes from sugars, with titers above 4 g/L approaching commercialization.

By Dr. Revathy Mohan V.R., MBBS · 3 days ago · 6 min read

Biotechnology·Becker H

Anthropic buys Mithril Medicine, shares early Claude drug development results

Anthropic acquired Mithril Medicine and disclosed early Claude-assisted drug development work with six partners across biotech and pharma.

Oct 28, 2026

Biotechnology·ACC-PRO

Astellas signs $400M AI Proteins deal for de novo miniproteins

Astellas entered a potential $400 million partnership with AI Proteins to discover de novo miniproteins and expand its…

Oct 22, 2026

Biotechnology·ACC-PRO

Hengrui’s China Biopharma Playbook Powers Global Licensing Deals

Hengrui’s rise from generic maker to global innovator centers on early R&D depth, platform science, and licensing deals…

Oct 21, 2026

Biotechnology·Br J Cancer

De Novo Metalloprotease Design Reaches Selective Protein Cleavage

Researchers designed programmable metalloproteases that cleave target peptides and disease proteins with high selectivity, including TDP-43, amyloid-β and…

Oct 21, 2026

Biotechnology·ACC-PRO

OrbiMed raises $3B to expand Asia biotech investing

OrbiMed raised $3 billion across global and Asia funds, boosting capital for biotech, medtech and life sciences investing.

Oct 17, 2026

Biotechnology·ACC-PRO

City Therapeutics IPO Raises $200M as Frazier SPAC Lists on Nasdaq

City Therapeutics raised $200 million in an upsized IPO while Frazier Life Sciences launched a new biotech-focused SPAC…

Oct 17, 2026

Biotechnology·ACC-PRO

AstraZeneca signs $1.5B insitro deal for AI target discovery in liver and heart disease

AstraZeneca will pay insitro $40 million upfront to use its AI platform to discover drug targets for MASH…

Oct 16, 2026

Biotechnology·ACC-PRO

City Therapeutics raises $200M to advance RNAi pipeline on Nasdaq

City Therapeutics priced an upsized $200 million IPO to fund RNAi programs in thrombosis, retinal disease and anemia…

Oct 16, 2026

Biotechnology

Clinical evidence, research, and medical intelligence in Biotechnology.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.